Manufacturers should ensure that, at the time of the marketing authorization, they have in place an appropriate pharmacovigilance system including the services of a qualified person responsible for monitoring pharmacovigilance and the necessary means for the notification of adverse reactions that occur in any of the countries where the product is marketed.